Brian Abrahams Analyst Performance

Analyst at Royal Bank Of Canada

Brian Abrahams is a stock analyst at Royal Bank Of Canada in the medical sector, covering 45 publicly traded companies. Over the past year, Brian Abrahams has issued 60 stock ratings, including buy and hold recommendations. While full access to Brian Abrahams' proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Brian Abrahams' coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 256 Last 10 Years
Buy Recommendations: 70.59% 180 Buy Ratings
Companies Covered: 45 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	70.6%	180 ratings
Hold	29.4%	75 ratings
Sell	0.0%	0 ratings

Out of 255 total stock ratings issued by Brian Abrahams at Royal Bank Of Canada, the majority (70.6%) have been Buy recommendations, followed by 29.4% Hold.

Best & Worst Calls

Best Call
0000.0%
SAGE
Apr 2020
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
SRRA
May 2016
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	97.8% of companies on NASDAQ	44 companies
NYSE	2.2% of companies on NYSE	1 company

Brian Abrahams, an analyst at Royal Bank Of Canada, currently covers 45 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 45 companies	100.0%

Brian Abrahams of Royal Bank Of Canada specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 26 companies	57.8%
PHARMACEUTICAL PREPARATIONS 11 companies	24.4%
MED - DRUGS 5 companies	11.1%
BIOTECHNOLOGY 2 companies	4.4%
MED - OUTP/HM CRE 1 company	2.2%

About Brian Abrahams

Dr. Brian Abrahams joined RBC Capital Markets in July 2017 as a senior analyst covering the biotechnology sector. He has 15 years of experience following large, mid, and small cap biotech companies, and prior to RBC spent time in biotechnology equity research at Jefferies, Wells Fargo, and CIBC World Markets / Oppenheimer & Co. He is a licensed non-practicing physician and holds a medical degree from the Albert Einstein College of Medicine. He did his undergraduate studies at Yale University, where he graduated magna cum laude with a Bachelor of Science degree in Molecular Biophysics & Biochemistry.

Follow on LinkedIn

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
MLTX MoonLake Immunotherapeutics	9/29/2025	Reiterated Rating	$6.86	$10.00	Sector Perform
APGE Apogee Therapeutics	9/25/2025	Initiated Coverage	$38.42	$60.00	Outperform
CDTX Cidara Therapeutics	9/24/2025	Set Price Target	$88.16	$137.00	Outperform
INCY Incyte	9/24/2025	Boost Price Target	$84.54	$81.00	Sector Perform
KYMR Kymera Therapeutics	9/16/2025	Initiated Coverage	$47.28	$70.00	Outperform
NBIX Neurocrine Biosciences	9/5/2025	Boost Price Target	$143.76	$149.00	Outperform
SION Sionna Therapeutics	9/3/2025	Initiated Coverage	$25.39	$22.00	Sector Perform
XENE Xenon Pharmaceuticals	9/2/2025	Reiterated Rating	$39.12	$55.00	Outperform
AARD Aardvark Therapeutics	8/14/2025	Lower Price Target	$11.44	$19.00	Outperform
XENE Xenon Pharmaceuticals	8/12/2025	Lower Price Target	$36.96	$55.00	Outperform
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
PTCT PTC Therapeutics	8/8/2025	Reiterated Rating	$46.87	$63.00	Outperform
ETNB 89BIO	8/8/2025	Lower Price Target	$8.92	$11.00	Sector Perform
GILD Gilead Sciences	8/8/2025	Boost Price Target	$119.21	$98.00	Sector Perform
ACAD ACADIA Pharmaceuticals	8/7/2025	Boost Price Target	$23.84	$40.00	Outperform
VRTX Vertex Pharmaceuticals	8/5/2025	Lower Price Target	$389.93	$405.00	Sector Perform
PRTA Prothena	8/5/2025	Lower Price Target	$7.28	$10.00	Sector Perform
REGN Regeneron Pharmaceuticals	8/4/2025	Boost Price Target	$569.71	$695.00	Sector Perform
BIIB Biogen	8/1/2025	Boost Price Target	$126.28	$219.00	Outperform
NBIX Neurocrine Biosciences	7/31/2025	Lower Price Target	$129.41	$144.00	Outperform
INCY Incyte	7/30/2025	Boost Price Target	$77.88	$72.00	Sector Perform
SRPT Sarepta Therapeutics	7/17/2025	Lower Price Target	$21.46	$23.00	Sector Perform
BCRX BioCryst Pharmaceuticals	6/30/2025	Reiterated Rating	$9.23	$13.00	Outperform
BIIB Biogen	6/25/2025	Set Price Target	$126.16	$213.00	Outperform
CDTX Cidara Therapeutics	6/24/2025	Upgrade	$49.86	$75.00	Moderate Buy
ACAD ACADIA Pharmaceuticals	6/23/2025	Boost Price Target	$22.12	$38.00	Outperform
VRTX Vertex Pharmaceuticals	6/17/2025	Set Price Target	$448.47	$420.00	Sector Perform
REGN Regeneron Pharmaceuticals	5/27/2025	Reiterated Rating	$599.20	$662.00	Sector Perform
CTNM Contineum Therapeutics	5/15/2025	Reiterated Rating	$3.72	$31.00	Outperform
KPTI Karyopharm Therapeutics	5/13/2025	Lower Price Target	$5.40	$33.00	Outperform
XENE Xenon Pharmaceuticals	5/13/2025	Lower Price Target	$29.93	$55.00	Outperform
CRBP Corbus Pharmaceuticals	5/7/2025	Lower Price Target	$6.34	$58.00	Outperform
VRTX Vertex Pharmaceuticals	5/6/2025	Boost Price Target	$434.64	$423.00	Sector Perform
BCRX BioCryst Pharmaceuticals	5/6/2025	Reiterated Rating	$10.40	$13.00	Outperform
BIIB Biogen	5/2/2025	Lower Price Target	$122.38	$205.00	Outperform
INCY Incyte	4/30/2025	Boost Price Target	$61.11	$67.00	Sector Perform
REGN Regeneron Pharmaceuticals	4/30/2025	Lower Price Target	$586.51	$943.00	Outperform
BIIB Biogen	4/22/2025	Boost Price Target	$117.63	$225.00	Outperform
LEGN Legend Biotech	4/22/2025	Reiterated Rating	$33.48	$84.00	Outperform
NBIX Neurocrine Biosciences	4/14/2025	Upgrade	$90.87	$137.00	Outperform
BCRX BioCryst Pharmaceuticals	4/11/2025	Reiterated Rating	$6.55	$11.00	Outperform

VRTX Vertex Pharmaceuticals	4/1/2025	Boost Price Target	$487.06	$420.00	Sector Perform
SRPT Sarepta Therapeutics	3/31/2025	Downgrade	$70.41	$87.00	Sector Perform
MLTX MoonLake Immunotherapeutics	3/18/2025	Initiated Coverage	$38.67	$67.00	Outperform
AARD Aardvark Therapeutics	3/10/2025	Initiated Coverage	$10.13	$21.00	Outperform
GHRS GH Research	3/7/2025	Initiated Coverage	$10.55	$31.00	Outperform
SRPT Sarepta Therapeutics	2/27/2025	Lower Price Target	$107.24	$161.00	Outperform
BCRX BioCryst Pharmaceuticals	2/25/2025	Reiterated Rating	$8.11	$11.00	Outperform
PRTA Prothena	2/21/2025	Lower Price Target	$15.61	$20.00	Sector Perform
VRTX Vertex Pharmaceuticals	2/20/2025	Boost Price Target	$475.68	$408.00	Sector Perform
KPTI Karyopharm Therapeutics	2/20/2025	Reiterated Rating	$9.41	$45.00	Outperform
BIIB Biogen	2/13/2025	Lower Price Target	$135.56	$225.00	Outperform
GILD Gilead Sciences	2/12/2025	Boost Price Target	$103.52	$90.00	Sector Perform
VRTX Vertex Pharmaceuticals	2/11/2025	Boost Price Target	$459.15	$407.00	Sector Perform
INCY Incyte	2/11/2025	Lower Price Target	$68.30	$68.00	Sector Perform
PLRX Pliant Therapeutics	2/10/2025	Downgrade	$7.79	$4.00	Sector Perform
KPTI Karyopharm Therapeutics	2/10/2025	Reiterated Rating	$9.77	$45.00	Outperform
NBIX Neurocrine Biosciences	2/7/2025	Lower Price Target	$122.00	$148.00	Sector Perform
GILD Gilead Sciences	2/3/2025	Reiterated Rating	$99.12	$84.00	Sector Perform
AXSM Axsome Therapeutics	1/29/2025	Reiterated Rating	$104.53	$139.00	Outperform
ITCI Intra-Cellular Therapies	1/22/2025	Reiterated Rating	$127.40	$132.00	Sector Perform

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.